<DOC>
	<DOC>NCT01388166</DOC>
	<brief_summary>The objective of this observational study is to collect and evaluate data on medication adherence of patients on maintenance COPD therapy with long-acting anticholinergic (e.g. Spiriva® delivered by HandiHaler® or Respimat®) using the MMAS-8 questionnaire.</brief_summary>
	<brief_title>ADESPI: Adherence to Spiriva® in Patients With COPD (Chronic Obstructive Pulmonary Disease), Measured by Morisky-8 (MMAS-8) Scale, in Routine Medical Practice</brief_title>
	<detailed_description>Purpose:</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criteria: Male and female ambulatory outpatients being seen in a participating physicians office for routine care, Patients with a clinical diagnosis of COPD and already being treated with the maintenance therapy with longacting anticholinergic (Tiotropium (Spiriva® HandiHaler® or Respimat®) at least 1 month and within product label Patient fluent in language of questionnaire and having the cognitive and functional abilities required to fill in the questionnaire alone Exclusion criteria: Uncooperative patients as judged by the physician Patients with any conditions excluded as per Country specific package insert Patients currently enrolled in any clinical trial which requires a change in medication for their respiratory problems.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>